New MRI dye could spot hidden prostate cancer cells

NCT ID NCT04261777

Terminated Diagnosis Sponsor: Saving Patients' Lives Medical B.V. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tested whether an iron-based contrast agent called Ferumoxtran-10 (Ferrotran®) could improve MRI scans to find prostate cancer that has spread to lymph nodes. The study involved 172 men with newly diagnosed prostate cancer at intermediate to high risk of spread. Each patient received the contrast agent before MRI, and the results were compared to standard MRI and tissue samples after surgery. The trial was terminated early, so final conclusions are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ferumoxtran-10 (Ferrotran®), an iron-based contrast agent given as an intravenous infusion before MRI
What this could lead to: If successful, this could provide a more accurate, non-invasive way to detect cancer spread to lymph nodes in prostate cancer patients, potentially reducing unnecessary surgeries.
What could go wrong: The trial was terminated early, so results may be incomplete. The approach is still experimental and may not prove better than current methods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic neoplasm Neoplasm Metastasis prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTASIS PROSTATE CANCER PROSTATECTOMY

Contacts and locations

Locations

Canisius-Wilhelmina Ziekenhuis Nijmegen

Nijmegen, 6532, Netherlands
Charité - Universitätsklinikum Berlin

Berlin, State of Berlin, 10117, Germany
Inselspital-Universitätsspital Bern

Bern, 3010, Switzerland
Nederlands Kanker Instituut Antoni van Leeuwenhoek

Amsterdam, 1006, Netherlands
Radboud University Medical Center

Nijmegen, 6525, Netherlands
Universitair Ziekenhuis Ghent

Ghent, 9000, Belgium
Universitätsklinikum Bonn

Bonn, 53127, Germany
Universitätsklinikum Carl Gustav Carus

Dresden, 01307, Germany
Universitätsklinikum Düsseldorf

Düsseldorf, 40225, Germany
Universitätsklinikum Essen

Essen, 45147, Germany
Universitätsklinikum Köln

Cologne, 50937, Germany
Universitätsklinikum Leipzig

Leipzig, 04103, Germany
Universitätsklinikum Schleswig-Holstein Lübeck

Lübeck, 23538, Germany
Universitätsmedizin Mannheim Medizinische Fakultät Mannheim der Universität Heidelberg

Mannheim, 68167, Germany
Vivantes Klinikum Am Urban

Berlin, 10967, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.